Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia | Zendy

Christine Katlama | Zendy; Cathia Soulié | Zendy; Fabienne Caby | Zendy; Alexis Denis | Zendy; Catherine Blanc | Zendy; L Schneider | Zendy; M.A. Valantin | Zendy; Roland Tubiana | Zendy; M. Kirstetter | Zendy; E. Valdenassi | Zendy; Thuy Nguyen | Zendy; Gilles Peytavin | Zendy; Vincent Cálvez | Zendy; AnneGeneviève Marcelin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

Author(s) -

Christine Katlama,

Cathia Soulié,

Fabienne Caby,

Alexis Denis,

Catherine Blanc,

L Schneider,

M.A. Valantin,

Roland Tubiana,

M. Kirstetter,

E. Valdenassi,

Thuy Nguyen,

Gilles Peytavin,

Vincent Cálvez,

AnneGeneviève Marcelin

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw186

Subject(s) - dolutegravir , integrase inhibitor , elvitegravir , medicine , viral load , regimen , raltegravir , drug resistance , integrase , virology , tolerability , genotyping , resistance mutation , maraviroc , gastroenterology , human immunodeficiency virus (hiv) , antiretroviral therapy , adverse effect , genotype , biology , reverse transcriptase , polymerase chain reaction , biochemistry , microbiology and biotechnology , gene

Reducing drug burden is a key challenge for achieving lifelong suppressive HIV therapy. Dolutegravir, with a high potency, long half-life and high genetic barrier, offers potential for monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research